ArticleClinical and experimental vaccine research2024

Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.

Renan James Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.